E7046

DRUG2 trials

Sponsors

Eisai Inc., Adlai Nortye Biopharma Co., Ltd.

Conditions

Neoadjuvant Therapy in Rectal CancerTumors

Phase 1

Study of E7046 in Subjects With Selected Advanced Malignancies

TerminatedNCT02540291

Eisai Inc.Tumors

Start: 2015-07-30End: 2018-02-27Updated: 2020-02-17

Preoperative Radiotherapy and E7046 in Rectum Cancer

CompletedNCT03152370

Adlai Nortye Biopharma Co., Ltd.Neoadjuvant Therapy in Rectal Cancer

Start: 2017-05-17End: 2021-09-30Updated: 2021-10-04

Related Papers

AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC): A single-arm, open-label, multicenter, phase Ib study.

Journal of Clinical Oncology2024-06-01

First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE<sub>2</sub>-receptor E-type 4 (EP4), in patients with advanced cancers

Journal for ImmunoTherapy of Cancer2020-06-0169 citations

Phase I study of E7046, a novel PGE<sub>2</sub> receptor type 4 inhibitor, in patients with advanced solid tumors: Clinical results and effects on myeloid- and T-lymphoid cell-mediated immunosuppression.

Journal of Clinical Oncology2018-02-103 citations

Abstract 4607: Specific inhibition of PGE2-EP4 signaling by E7046 promotes anti-tumor activity of checkpoint blockade agents through boosting cytotoxic T cell activity

Cancer Research2017-07-012 citations

Phase 1 study of E7046, an inhibitor of the PGE<sub>2</sub> receptor EP-4, that targets immunosuppressive myeloid cells in the tumor microenvironment (NCT02540291).

Journal of Clinical Oncology2016-05-201 citations